UGT1A9 and neutropenia: Although only about 20% to 30% of patients who had the UGT1A9*22 polymorphism suffered severe toxicity, by classifying these patients as a high-risk group for irinotecan toxicity, clinicians could follow these patients more closely for severe diarrhea or neutropenia.